Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.36 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17321030 | 0.94 | ALOX15 (0.41) | ALOX15KCNA2KCNA1KMT2AMTNR1A | |
| SCHEMBL15898910 | 0.83 | KIF11 (0.33) | ALOX15MTNR1AMAPT | |
| SCHEMBL15898860 | 0.82 | MTNR1A (0.33) | ALOX15KCNA2KCNA1MTNR1A | |
| SCHEMBL15898930 | 0.80 | KIF11 (0.33) | ALOX15MTNR1AMAPT | |
| SCHEMBL17321018 | 0.77 | MAPT (0.55) | ALOX15KMT2AALDH1A1MEN1POLB | |
| SCHEMBL17321017 | 0.77 | THRB (0.46) | ALOX15MTNR1AALDH1A1POLBTSHR | |
| SCHEMBL22817321 | 0.76 | SCN9A (0.33) | ALOX15ALDH1A1KDM4ETSHR | |
| SCHEMBL17321027 | 0.74 | ALOX15 (0.45) | ALOX15KCNA2KCNA1KMT2AMTNR1A | |
| SCHEMBL17321014 | 0.73 | PDE10A (0.43) | MTNR1AALDH1A1POLBKDM4EHSD17B10 | |
| SCHEMBL17324189 | 0.73 | MTNR1A (0.40) | KMT2AMTNR1AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | ALOX15 1874/4885KCNA2 1423/4885KCNA1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.